Q-omics provides the consensus-scored THBS3 profile across patient tissues and cancer cell-line models. THBS3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, THBS3 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, THBS3 protein abundance shows 22,969 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, KIRP, and PDAC as cancer lineages where THBS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for THBS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes THBS3 survival associations across molecular data types. THBS3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible THBS3 RNA expression–survival associations across cancer types. High THBS3 expression shows unfavorable associations in KIRC, MESO, ACC, LGG, COAD and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for THBS3 RNA expression.
This table summarizes THBS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for THBS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. THBS3 shows lower tumor expression in KICH and UCEC and higher tumor expression in KIRP, LIHC, KIRC and LUAD. The KIRP box plot shows higher THBS3 RNA expression in tumor versus normal tissue (log2 FC = +0.891, t-test p < 0.001).
This table shows molecular features associated with THBS3 in patient tissues and cancer cell lines. In patient samples, THBS3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, THBS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
